The DOI matches its Crossref record; 130 of the 130 references it cites were found in a registry or an index.
Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice
Abstract
Second-generation antipsychotics (SGA) are being used more often than ever before in children and adolescents with psychotic and a wide range of non-psychotic disorders. Several SGA have received regulatory approval for some paediatric indications in various countries, but off-label use is still frequent. The aim of this paper was to perform a systematic review and critically evaluate the literature on cardiometabolic and endocrine side-effects of SGA in children and adolescents through a Medline/Pubmed/Google Scholar search of randomized, placebo controlled trials of antipsychotics in children and adolescents (<18 years old) until February 2010. In total, 31 randomized, controlled studies including 3595 paediatric patients were identified. A review of these data confirmed that SGA are associated with relevant cardiometabolic and endocrine side-effects, and that children and adolescents have a high liability to experience antipsychotic induced hyperprolactinaemia, weight gain and associated metabolic disturbances. Only weight change data were sufficiently reported to conduct a formal meta-analysis. In 24 trials of 3048 paediatric patients with varying ages and diagnoses, ziprasidone was associated with the lowest weight gain (−0.04 kg, 95% confidence interval [CI]: −0.38 to +0.30), followed by aripiprazole (0.79 kg, 95% CI: 0.54 to 1.04], quetiapine (1.43 kg, 95% CI: 1.17 to 1.69) and risperidone (1.76 kg, 95% CI: 1.27 to 2.25) were intermediate, and olanzapine was associated with weight gain the most (3.45 kg, 95% CI: 2.93 to 3.97). Significant weight gain appeared to be more prevalent in patients with autistic disorder who were also younger and likely less exposed to antipsychotics previously. These data clearly suggest that close screening and monitoring of metabolic side effects is warranted and that the least cardiometabolically problematic agents should be used first whenever possible. A good collaboration between child- and adolescent psychiatrists, general practitioners and paediatricians is essential to maximize overall outcomes and to reduce the likelihood of premature cardiovascular morbidity and mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yatham, L., & Malhi, G. (2011) · Oxford University Press eBooks · doi:10.1093/med/9780199562305.001.0001 · Cited by 3,506
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574
Consensus development conference on antipsychotic drugs and obesity and diabetes
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004) · Diabetes Care · doi:10.2337/diacare.27.2.596 · Cited by 1,554
Fernández, J. R., Redden, D. T., Pietrobelli, A., & Allison, D. B. (2004) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2004.06.044 · Cited by 1,418
Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes
Boehm, G., Racoosin, J. A., Laughren, T. P., & Katz, R. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.2088-a · Cited by 1,204
Lipid screening and cardiovascular health in childhood
Daniels, S. R., Greer, F. R., & and the Committee on Nutrition (2008) · Pediatrics · doi:10.1542/peds.2008-1349 · Cited by 1,178
Report of the Second Task Force on Blood Pressure Control in Children—1987
Task Force on Blood Pressure Control in Children (1987) · Pediatrics · doi:10.1542/peds.79.1.1 · Cited by 1,148
Report of the second Task Force on Blood Pressure Control in Children―1987
Horan, M. J. (1987) · PEDIATRICS · Cited by 1,125
Kahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P., Gheorghe, M. D., Rybakowski, J. K., Galderisi, S., Libiger, J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60486-9 · Cited by 1,088
Correll, C. U. (2009) · JAMA · doi:10.1001/jama.2009.1549 · Cited by 1,050 · cited 5×
“Patients who are previously unexposed to antipsychotics are particularly vulnerable to weight gain and this weight gain occurs rapidly within the first few weeks [25,122].”
BackgroundInfluentialSelf-citationDe Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., Holt, R. I. G., & Möller, H.-J. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.01.005 · Cited by 951 · cited 13×
“MetS is a constellation of physical and laboratory features that is more common in obese patients and predisposes adults and children to atherosclerotic CVD.”
BackgroundInfluentialThe metabolic syndrome in children and adolescents
Zimmet, P., Alberti, G., Kaufman, F., Tajima, N., Silink, M., Arslanian, S., Wong, G., Bennett, P., Shaw, J., & Caprio, S. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60958-1 · Cited by 937
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., Himelhoch, S., Fang, B., Peterson, E., Aquino, P. R., et al. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp116 · Cited by 907
Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles
Nasrallah, H. A. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002066 · Cited by 714
Antipsychotic-Induced Hyperprolactinaemia: Mechanisms, Clinical Features and Management
Haddad, P. M., & Wieck, A. (2004) · Drugs · doi:10.2165/00003495-200464200-00003 · Cited by 634 · cited 2×
“Signs and symptoms of hyperprolactinemia [20,59,71].”
BackgroundMetabolic syndrome in people with schizophrenia: a review
DE HERT, M., SCHREURS, V., VANCAMPFORT, D., & VAN WINKEL, R. (2009) · World Psychiatry · doi:10.1002/j.2051-5545.2009.tb00199.x · Cited by 634 · cited 1×
“Based on emerging data consisting of indirect comparisons only, it appears that children and adolescents are at higher risk than adults for antipsychotic-induced hyperprolactinaemia, weight gain and possibly associated metabolic abnormalities [3,7,15,21,24,26,31,37,51,54,74,75,101,102].”
BackgroundAripiprazole in the Treatment of Irritability in Children and Adolescents With Autistic Disorder
Owen, R., Sikich, L., Marcus, R. N., Corey-Lisle, P., Manos, G., McQuade, R. D., Carson, W. H., & Findling, R. L. (2009) · Pediatrics · doi:10.1542/peds.2008-3782 · Cited by 613
National Trends in the Outpatient Treatment of Children and Adolescents With Antipsychotic Drugs
Olfson, M., Blanco, C., Liu, L., Moreno, C., & Laje, G. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.6.679 · Cited by 591
Marcus, R. N., Owen, R., Kamen, L., Manos, G., McQuade, R. D., Carson, W. H., & Aman, M. G. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3181b76658 · Cited by 566
Shea, S., Turgay, A., Carroll, A., Schulz, M., Orlik, H., Smith, I., & Dunbar, F. (2004) · Pediatrics · doi:10.1542/peds.2003-0264-f · Cited by 566
Nasrallah, H. A., Meyer, J. M., Goff, D. C., McEvoy, J. P., Davis, S. M., Stroup, T. S., & Lieberman, J. A. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.06.026 · Cited by 556
Leucht, S., Komossa, K., Rummel-Kluge, C., Corves, C., Hunger, H., Schmid, F., Asenjo Lobos, C., Schwarz, S., & Davis, J. M. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08030368 · Cited by 490
Sikich, L., Frazier, J. A., McClellan, J., Findling, R. L., Vitiello, B., Ritz, L., Ambler, D., Puglia, M., Maloney, A. E., Michael, E., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08050756 · Cited by 478
Aman, M. G., De Smedt, G., Derivan, A., Lyons, B., Findling, R. L., & Risperidone Disruptive Behavior Study Group (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.8.1337 · Cited by 475
Endocrine and Metabolic Adverse Effects of Psychotropic Medications in Children and Adolescents
CORRELL, C. U., & CARLSON, H. E. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000220851.94392.30 · Cited by 403
Self-citationMcEvoy, J. P., Lieberman, J. A., Perkins, D. O., Hamer, R. M., Gu, H., Lazarus, A., Sweitzer, D., Olexy, C., Weiden, P., & Strakowski, S. D. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1050 · Cited by 377
A placebo-controlled trial of risperidone in Tourette syndrome
Scahill, L., Leckman, J. F., Schultz, R. T., Katsovich, L., & Peterson, B. S. (2003) · Neurology · doi:10.1212/01.wnl.0000055434.39968.67 · Cited by 362
Report of the Second Task Force on Blood Pressure Control in Children.
Zahka, K. G. (1987) · PubMed · Cited by 341
Ziprasidone Treatment of Children and Adolescents With Tourette's Syndrome: A Pilot Study
SALLEE, F. R., KURLAN, R., GOETZ, C. G., SINGER, H., SCAHILL, L., LAW, G., DITTMAN, V. M., & CHAPPELL, P. B. (2000) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200003000-00010 · Cited by 341
Effects of Risperidone on Conduct and Disruptive Behavior Disorders in Children With Subaverage IQs
SNYDER, R., TURGAY, A., AMAN, M., BINDER, C., FISMAN, S., & CARROLL, A. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200209000-00002 · Cited by 335
Olanzapine Versus Placebo in the Treatment of Adolescents With Bipolar Mania
Tohen, M., Kryzhanovskaya, L., Carlson, G., DelBello, M., Wozniak, J., Kowatch, R., Wagner, K., Findling, R., Lin, D., Robertson-Plouch, C., et al. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06111932 · Cited by 315
A Double-Blind Pilot Study of Risperidone in the Treatment of Conduct Disorder
FINDLING, R. L., McNAMARA, N. K., BRANICKY, L. A., SCHLUCHTER, M. D., LEMON, E., & BLUMER, J. L. (2000) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200004000-00021 · Cited by 309
Sikich, L., Hamer, R. M., Bashford, R. A., Sheitman, B. B., & Lieberman, J. A. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300327 · Cited by 308
Findling, R. L., Robb, A., Nyilas, M., Forbes, R. A., Jin, N., Ivanova, S., Marcus, R., McQuade, R. D., Iwamoto, T., & Carson, W. H. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07061035 · Cited by 271
Klein, D. J., Cottingham, E. M., Sorter, M., Barton, B. A., & Morrison, J. A. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.12.2072 · Cited by 271
Álvarez-Jiménez, M., González-Blanch, C., Crespo-Facorro, B., Hetrick, S., Rodríguez-Sánchez, J. M., Pérez-Iglesias, R., & Vázquez-Barquero, J. L. (2008) · CNS Drugs · doi:10.2165/00023210-200822070-00002 · Cited by 264
Correll, C. U., Sheridan, E. M., & DelBello, M. P. (2010) · Bipolar Disorders · doi:10.1111/j.1399-5618.2010.00798.x · Cited by 255 · cited 3×
“Based on emerging data consisting of indirect comparisons only, it appears that children and adolescents are at higher risk than adults for antipsychotic-induced hyperprolactinaemia, weight gain and possibly associated metabolic abnormalities [3,7,15,21,24,26,31,37,51,54,74,75,101,102].”
BackgroundSelf-citationAntipsychotic Use in Children and Adolescents: Minimizing Adverse Effects to Maximize Outcomes
CORRELL, C. U. (2008) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31815b5cb1 · Cited by 254
Self-citationDe Hert, M., Schreurs, V., Sweers, K., Van Eyck, D., Hanssens, L., Šinko, S., Wampers, M., Scheen, A., Peuskens, J., & van Winkel, R. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.01.028 · Cited by 247
Self-citationThe metabolic syndrome and schizophrenia
Meyer, J. M., & Stahl, S. M. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01317.x · Cited by 245
Simon, V., van Winkel, R., & De Hert, M. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08r04392 · Cited by 239
Self-citationBuitelaar, J. K., van der Gaag, R. J., Cohen-Kettenis, P., & Melman, C. T. M. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0405 · Cited by 236
Haas, M., DelBello, M. P., Pandina, G., Kushner, S., Van Hove, I., Augustyns, I., Quiroz, J., & Kusumakar, V. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00750.x · Cited by 231
Maayan, L., Vakhrusheva, J., & Correll, C. U. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.21 · Cited by 230
Self-citationFindling, R. L., Nyilas, M., Forbes, R. A., McQuade, R. D., Jin, N., Iwamoto, T., Ivanova, S., Carson, W. H., & Chang, K. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05164yel · Cited by 224
Hollander, E., Wasserman, S., Swanson, E. N., Chaplin, W., Schapiro, M. L., Zagursky, K., & Novotny, S. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.541 · Cited by 220
De Hert, M., Vancampfort, D., Correll, C. U., Mercken, V., Peuskens, J., Sweers, K., van Winkel, R., & Mitchell, A. J. (2011) · British Journal of Psychiatry · doi:10.1192/bjp.bp.110.084665 · Cited by 217
Self-citationTrends in Antipsychotic Drug Use by Very Young, Privately Insured Children
Olfson, M., Crystal, S., Huang, C., & Gerhard, T. (2010) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2009.09.003 · Cited by 215
Risperidone in Children With Autism: Randomized, Placebo-Controlled, Double-Blind Study
Nagaraj, R., Singhi, P., & Malhi, P. (2006) · Journal of Child Neurology · doi:10.1177/08830738060210060801 · Cited by 214
Nielsen, J., Skadhede, S., & Correll, C. U. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.78 · Cited by 207
Self-citationThe neural network underlying locomotion in lamprey-synaptic and cellular mechanisms
Grillner, S., & Matsushima, T. (1991) · Neuron · doi:10.1016/0896-6273(91)90069-c · Cited by 203
Morrato, E. H., Druss, B., Hartung, D. M., Valuck, R. J., Allen, R., Campagna, E., & Newcomer, J. W. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.179 · Cited by 199
Rani, F., Murray, M. L., Byrne, P. J., & Wong, I. C. K. (2008) · Pediatrics · doi:10.1542/peds.2007-2008 · Cited by 190
Kumra, S., Oberstar, J. V., Sikich, L., Findling, R. L., McClellan, J. M., Vinogradov, S., & Charles Schulz, S. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm109 · Cited by 186
Sertindole: pharmacological and clinical profile and role in the treatment of schizophrenia
Spina, E., & Zoccali, R. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.5.629 · Cited by 184
Correll, C. U., Penzner, J. B., Parikh, U. H., Mughal, T., Javed, T., Carbon, M., & Malhotra, A. K. (2006) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2005.08.007 · Cited by 184
Self-citationHaupt, D. W., Rosenblatt, L. C., Kim, E., Baker, R. A., Whitehead, R., & Newcomer, J. W. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08030383 · Cited by 183
Luby, J., Mrakotsky, C., Stalets, M. M., Belden, A., Heffelfinger, A., Williams, M., & Spitznagel, E. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.575 · Cited by 177
Effects of Short- and Long-Term Risperidone Treatment on Prolactin Levels in Children with Autism
Anderson, G. M., Scahill, L., McCracken, J. T., McDougle, C. J., Aman, M. G., Tierney, E., Arnold, L. E., Martin, A., Katsovich, L., Posey, D. J., et al. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.032 · Cited by 176
DelBello, M. P., Chang, K., Welge, J. A., Adler, C. M., Rana, M., Howe, M., Bryan, H., Vogel, D., Sampang, S., Delgado, S. V., et al. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00728.x · Cited by 173
Morrato, E. H., Newcomer, J. W., Kamat, S., Baser, O., Harnett, J., & Cuffel, B. (2009) · Diabetes Care · doi:10.2337/dc08-1720 · Cited by 171
Acute and Long-Term Safety and Tolerability of Risperidone in Children with Autism
Aman, M. G., Arnold, M. D., McDougle, C. J., Vitiello, B., Scahill, L., Davies, M., McCracken, J. T., Tierney, E., Nash, P. L., Posey, D. J., et al. (2005) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2005.15.869 · Cited by 170
Elman, I., Borsook, D., & Lukas, S. E. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301051 · Cited by 169
Patel, J. K., Buckley, P. F., Woolson, S., Hamer, R. M., McEvoy, J. P., Perkins, D. O., Lieberman, J. A., & for the CAFE investigators (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.03.025 · Cited by 169
Kryzhanovskaya, L., Schulz, S. C., Mcdougle, C., Frazier, J., Dittmann, R., Robertson-Plouch, C., Bauer, T., Xu, W., Wang, W., Carlson, J., et al. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3181900404 · Cited by 168
CORRELL, C. U. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318040b25f · Cited by 158
Self-citationVancampfort, D., Knapen, J., Probst, M., van Winkel, R., Deckx, S., Maurissen, K., Peuskens, J., & Binder, M. D. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2010.03.011 · Cited by 157
Metabolic Screening in Children Receiving Antipsychotic Drug Treatment
Morrato, E. H., Nicol, G. E., Maahs, D. M., Druss, B. G., Hartung, D. M., Valuck, R. J., Campagna, E. J., & Newcomer, J. W. (2010) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpediatrics.2010.48 · Cited by 154
Second-Generation Antipsychotic Medications in Children and Adolescents
Cheng-Shannon, J., McGough, J. J., Pataki, C., & McCracken, J. T. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2004.14.372 · Cited by 152
Haas, M., Unis, A. S., Armenteros, J. L., Copenhaver, M. D., Quiroz, J. A., & Kushner, S. F. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.0144 · Cited by 148
Newcomer, J. W., Nasrallah, H. A., & Loebel, A. D. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000142281.85207.d5 · Cited by 139
van Bellinghen, M., & Troch, C. (2001) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/104454601750143348 · Cited by 138
Hellings, J. A., Zarcone, J. R., Crandall, K., Wallace, D., & Schroeder, S. R. (2001) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/10445460152595559 · Cited by 132
Prolactin Levels During Long-Term Risperidone Treatment in Children and Adolescents
Findling, R. L., Kusumakar, V., Daneman, D., Moshang, T., Smedt, G. D., & Binder, C. E. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1113 · Cited by 128
Armenteros, J. L., Lewis, J. E., & Davalos, M. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3180323354 · Cited by 127
Jensen, P. S., Buitelaar, J. K., Pandina, G., Binder, C. E., & Haas, M. (2006) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-006-0580-1 · Cited by 115
Tramontina, S., Zeni, C., Ketzer, C. R., Pheula, G. F., Narvaez, J. C. D. M., & Rohde, L. A. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04726 · Cited by 115
Roke, Y., van Harten, P. N., Boot, A. M., & Buitelaar, J. K. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.0120 · Cited by 115
Stigler, K. A., Potenza, M. N., Posey, D. J., & McDougle, C. J. (2004) · Pediatric Drugs · doi:10.2165/00148581-200406010-00003 · Cited by 114
Weight gain in antipsychotic-naive patients: a review and meta-analysis
Tarricone, I., Gozzi, B. F., Serretti, A., Grieco, D., & Berardi, D. (2009) · Psychological Medicine · doi:10.1017/s0033291709990407 · Cited by 114
Adverse Endocrine and Metabolic Effects of Psychotropic Drugs: Selective Clinical Review
Bhuvaneswar, C. G., Baldessarini, R. J., Harsh, V., & Alpert, J. E. (2009) · CNS Drugs · doi:10.2165/11530020-000000000-00000 · Cited by 108
The Role of Psychosocial Interventions in Bipolar II Disorder: What Do We Know?
Swartz, H. A. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.0508e15 · Cited by 107
Children with Schizophrenia: Clinical Picture and Pharmacological Treatment
Masi, G., Mucci, M., & Pari, C. (2006) · CNS Drugs · doi:10.2165/00023210-200620100-00005 · Cited by 106
DelBello, M. P., Adler, C. M., Whitsel, R. M., Stanford, K. E., & Strakowski, S. M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0520 · Cited by 103
Haas, M., Eerdekens, M., Kushner, S. F., Singer, J., Augustyns, I., Quiroz, J. A., Pandina, G., & Kusumakar, V. (2009) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.107.046177 · Cited by 103
Morrato, E. H., Newcomer, J. W., Allen, R. R., & Valuck, R. J. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0219 · Cited by 103
Clinicians' recognition of the metabolic adverse effects of antipsychotic medications
Buckley, P. F., Miller, D. D., SINGER, B., ARENA, J., & Stirewalt, E. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.04.010 · Cited by 102
Findling, R. L., Johnson, J. L., McClellan, J., Frazier, J. A., Vitiello, B., Hamer, R. M., Lieberman, J. A., Ritz, L., McNamara, N. K., Lingler, J., et al. (2010) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2010.03.013 · Cited by 101 · cited 1×
“Thirty-one controlled studies with SGA in the defined target population were found including youth with different diagnoses, 29 double-blind trials [4,5,7,14,34,36,43,46,47,49,50,56,58,63, 64,73,81,82,85,86,104,111,112,114,118,123,126] and two studies without a placebo arm [35,57].”
BackgroundFraguas, D., Merchán‐Naranjo, J., Laita, P., Parellada, M., Moreno, D. M., Ruíz-Sancho, A., Cifuentes, A., Giráldez, M., & Arango, C. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0717 · Cited by 101
Correll, C. U. (2008) · International Review of Psychiatry · doi:10.1080/09540260801889179 · Cited by 98
Self-citationKinon, B., AHL, J. S. B., Liu‐Seifert, H., & Maguire, G. A. (2006) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2005.12.006 · Cited by 95
The role of GNAS and other imprinted genes in the development of obesity
Weinstein, L. S., Xie, T., Qasem, A., Wang, J., & Chen, M. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.222 · Cited by 95
Panagiotopoulos, C., Ronsley, R. J., Elbe, D., Davidson, J., & Smith, D. H. (2010) · Europe PMC (PubMed Central) · Cited by 88
DelBello, M. P., Versavel, M., Ice, K. S., Keller, D., & Miceli, J. J. (2008) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.008 · Cited by 76
The Effect of Atypical Antipsychotic Agents on Prolactin Levels in Children and Adolescents
Pappagallo, M., & Silva, R. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2004.14.359 · Cited by 75
Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents.
Findling, R. L. (2008) · PubMed · Cited by 74
The Effects of Atypical Antipsychotics on Serum Prolactin Levels
Hamner, M. B. (2002) · Annals of Clinical Psychiatry · doi:10.1023/a:1021138603935 · Cited by 74
Atypical neuroleptics in child and adolescent psychiatry
Remschmidt, H., Hennighausen, K., Heiset, P., Clement, W., & Schulz, E. (2000) · European Child & Adolescent Psychiatry · doi:10.1007/s007870070015 · Cited by 73
Binder, M. D., Kalnická, D., van Winkel, R., Wampers, M., Hanssens, L., Eyck, D. V., Scheen, A. J., & Peuskens, J. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1208 · Cited by 66
Canitano, R. (2004) · Brain and Development · doi:10.1016/j.braindev.2004.06.006 · Cited by 63
Clinical Drug Monitoring in Child and Adolescent Psychiatry: Side Effects of Atypical Neuroleptics
Fleischhaker, C., Heiser, P., Hennighausen, K., Herpertz‐Dahlmann, B., Holtkamp, K., Mehler‐Wex, C., Rauh, R., Remschmidt, H., Schulz, E., & Warnke, A. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.308 · Cited by 59
Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia.
Hanssens, L., Binder, M. D., Kalnická, D., van Winkel, R., Wampers, M., Eyck, D. V., Scheen, A. J., & Peuskens, J. (2007) · PubMed · doi:10.1097/yic.0b013e3280113d3b · Cited by 57
Vieweg, W. V. R., Sood, A. B., Pandurangi, A. K., & Silverman, J. J. (2005) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2004.00444.x · Cited by 56
Moreno, C., Merchán‐Naranjo, J., Álvarez, M., Baeza, I., Alda, J. A., Martínez‐Cantarero, C., Parellada, M., Sánchez, B., de la Serna, E., Giráldez, M., et al. (2010) · Bipolar Disorders · doi:10.1111/j.1399-5618.2010.00797.x · Cited by 54
Swadi, H. S., Craig, B. J., Pirwani, N. Z., Black, V., Buchan, J. C., & Bobier, C. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283320511 · Cited by 54
Metformin for Weight Control in Pediatric Patients on Atypical Antipsychotic Medication
Shin, L., Bregman, H. R., Breeze, J. L., Noyes, N., & Frazier, J. A. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.094 · Cited by 53
Gothefors, D., Adolfsson, R., Attvall, S., Erlinge, D., Jarbin, H., Lindström, K., von Hausswolff‐Juhlin, Y., Morgell, R., Toft, E., & Ösby, U. (2010) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2010.500397 · Cited by 50
Varley, C. K., & McClellan, J. (2009) · JAMA · doi:10.1001/jama.2009.1558 · Cited by 45
The Safety of Olanzapine in Adolescents With Schizophrenia or Bipolar I Disorder
Kryzhanovskaya, L. A., Robertson-Plouch, C. K., Xu, W., Carlson, J. L., Merida, K. M., & Dittmann, R. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m03538 · Cited by 43
Cohen, D., & Correll, C. U. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09ac05255 · Cited by 40
Self-citationSertindole: efficacy and safety in schizophrenia
Lindström, E., & Levander, S. E. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.13.1825 · Cited by 36
Review of antipsychotics in children and adolescents
Kapetanovic, S., & Simpson, G. M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.14.1871 · Cited by 33
[Prevention and treatment of somatic complications arising from the use of antipsychotics].
Cahn, W., Ramlal, D., Bruggeman, R., de Haan, L., Scheepers, F. E., van Soest, M. M., Assies, J., & Slooff, C. J. (2008) · PubMed · Cited by 32
Lindsay, R. L., Leone, S. L., & Aman, M. G. (2004) · Clinical Pediatrics · doi:10.1177/000992280404300504 · Cited by 28
Dosing Strategies for Antidepressant Clinical Trials
Robinson, D. S., & Khan, A. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000108980.47737.f8 · Cited by 25
Alacqua, M., Trifirò, G., Arcoraci, V., Germanò, E., Magazù, A., Calarese, T., Vita, G. D., Gagliano, C., & Spina, E. (2007) · Pharmacy World & Science · doi:10.1007/s11096-007-9139-6 · Cited by 24
Brown, G. G., McCarthy, G., Bischoff‐Grethe, A., Özyurt, İ. B., Greve, D. N., Potkin, S. G., Turner, J. A., Notestine, R. J., Calhoun, V. D., Ford, J. M., et al. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn149 · Cited by 23
Jerrell, J., Bacon, J., Burgis, J., & Menon, S. (2009) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2008.11.010 · Cited by 21
Hsu, C., Ried, L. D., Bengtson, M. A., Garman, P. M., McConkey, J. R., & Rahnavard, F. (2008) · Journal of the American Pharmacists Association · doi:10.1331/japha.2008.07007 · Cited by 21
Risperidone in pervasive developmental disorders
Erickson, C. A., Stigler, K. A., Posey, D. J., & McDougle, C. J. (2005) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.5.6.713 · Cited by 18
Atypical Antipsychotic-Induced Diabetes Mellitus in Child and Adolescent Psychiatry
Cohen, D., & Huinink, S. A. T. B. (2007) · CNS Drugs · doi:10.2165/00023210-200721120-00006 · Cited by 16
Self-citationDelBello, M. P., & Correll, C. U. (2010) · Bipolar Disorders · doi:10.1111/j.1399-5618.2010.00796.x · Cited by 15
Self-citationBiochemical risk factors for development of obesity in first-episode schizophrenia
Bodén, R., Haenni, A., Lindström, L., & Sundström, J. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.09.024 · Cited by 14
Findling, R. L., Çavuş, I., Pappadolulos, E., Backinsky, M., Schwartz, J. H., & Vanderburg, D. G. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.02.808 · Cited by 9
Hert, M. D., Vancampfort, D., Correll, C. U., Peuskens, J., van Winkel, R., & Mitchell, A. J. (2011) · European Psychiatry · doi:10.1016/s0924-9338(11)73892-5 · Cited by 8
Self-citationGLUCOSE ABNORMALITIES IN A NON-PSYCHOTIC PATIENT TREATED WITH RISPERIDONE
Lauwers, K., & Binder, M. D. (2005) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000162572.25203.7e · Cited by 4
Cited by
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488
Self-citationMetabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145
DE HERT, M., COHEN, D., BOBES, J., CETKOVICH‐BAKMAS, M., LEUCHT, S., NDETEI, D. M., NEWCOMER, J. W., UWAKWE, R., ASAI, I., MÖLLER, H., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00036.x · Cited by 870
Self-citationCorrell, C. U., Detraux, J., De Lepeleire, J., & De Hert, M. (2015) · World Psychiatry · doi:10.1002/wps.20204 · Cited by 820
“In children and adolescents (<18 years old), roughly the same hierarchy for risk of weight gain with these agents has been identified (23,34-36), yet at a higher level, likely due to less prior antipsychotic exposure (30).”
BackgroundSelf-citationAntipsychotic-associated weight gain: management strategies and impact on treatment adherence
Dayabandara, M., Hanwella, R., Ratnatunga, S., Seneviratne, S., Suraweera, C., & de Silva, V. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s113099 · Cited by 367
Metadata
- Authors
- De Hert, M., Dobbelaere, M., Sheridan, E. M., Cohen, D., & Correll, C. U.
- Venue
- European Psychiatry
- Publisher
- Cambridge University Press (CUP)
- Published
- 2011-04
- Volume
- 26
- Issue
- 3
- Pages
- 144-158
- ISSN
- 0924-9338 (ISSN-L)
- 1778-3585
- OpenAlex
- W2094107633
- Cited by
- 362
- References
- 130
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.